Sarepta Therapeutics, Inc. SRPT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s financing cash flow?
- Sarepta Therapeutics, Inc. (SRPT) reported financing cash flow of $241K in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Sarepta Therapeutics, Inc.'s financing cash flow decreased by 98.1% year-over-year, from $12.47M to $241K.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s financing cash flow has grown at a -26.0% compound annual growth rate (CAGR), from $561.57M to -$168.34M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.